Stock listing

Stockholm:BIOAB BioArctic AB Aktie

Home listing (Stockholm) of BioArctic AB

Follow BioArctic AB into a list and get an email when it puts out news.

Share price · OMXSTO:BIOA_B

289.00 SEK +1.60 (+0.6%)

Close on Oct 19, 2026

Past 3 months -10.4% · daily closes, Jul 7, 2026 – Oct 19, 2026, adjusted for splits
Day range
283.20 – 290.40 SEKOct 19, 2026
Volume
94,156 sharesOct 19, 2026
Market cap
25.65B SEKAt the close on Oct 19, 2026 · price × 88.74M shares outstanding
BioArctic AB logo

Prices by listing

ListingLastChangeVolumeOpenHighLowPrevious closePrice from
Frankfurt:B9A€25.36 EUR-0.66 (-2.5%)—€25.36€25.36€25.36€26.02Close on Oct 19, 2026

Daily closes

Last 3 months, Jul 20, 2026 – Oct 19, 2026 · OMXSTO:BIOA_B · SEK, adjusted for splits

DayCloseChange%OpenHighLowVolume
289.00+1.60+0.6%287.20290.40283.2094,156
287.40-5.60-1.9%293.20293.80287.2082,514
293.00-1.00-0.3%294.00294.40285.00142,326
294.00+6.40+2.2%288.20294.80285.20106,087
287.60-10.60-3.6%297.80298.60286.40121,809
298.20+2.80+0.9%295.00300.20294.6076,665
295.40+5.00+1.7%290.40298.80290.4063,548
290.40-5.00-1.7%293.00293.80285.20151,595
295.40-6.80-2.3%296.80300.40292.20174,546
302.20+1.00+0.3%304.00307.40296.00101,009
301.20-4.00-1.3%305.00309.20300.8068,861
305.20-1.80-0.6%305.80308.60300.00141,465
307.00-3.40-1.1%312.40312.40304.60116,389
310.40+4.80+1.6%306.20312.40305.0082,851
305.60-3.20-1.0%308.80314.80305.00163,377
308.80-4.40-1.4%313.80314.80307.80124,047
313.20-5.20-1.6%319.00320.80313.20136,470
318.40-3.60-1.1%322.00322.00315.40144,903
322.00-5.20-1.6%328.60332.80322.0077,947
327.20+6.80+2.1%320.40328.80319.20145,207
320.40-0.60-0.2%321.40323.20318.60102,370
321.00-3.60-1.1%323.40328.80321.00123,560
324.60+6.60+2.1%317.80324.60317.4061,799
318.00+0.60+0.2%321.00323.60317.6067,483
317.40-8.00-2.5%323.20325.80317.40100,030
325.40+5.80+1.8%319.60326.80319.6066,352
319.60-7.20-2.2%326.80328.80319.60107,055
326.80-4.00-1.2%329.00332.40326.6084,349
330.80-0.40-0.1%332.00333.20327.0085,328
331.20+2.60+0.8%329.20335.60326.60107,528
328.60-5.40-1.6%331.00333.40328.2065,248
334.00-12.20-3.5%345.80350.00334.00137,095
346.20+20.00+6.1%330.20349.00330.20402,604
326.20+6.00+1.9%320.20334.80319.40240,742
320.20+1.80+0.6%318.40324.00314.80124,105
318.40-12.60-3.8%329.40329.40317.60264,920
331.00+5.60+1.7%327.80337.60327.20304,957
325.40+3.40+1.1%325.00329.40317.80198,848
322.00-23.00-6.7%348.00360.00314.60928,957
345.00+15.20+4.6%332.40347.80332.40324,337
329.80-5.80-1.7%332.40337.80329.80157,912
335.60-1.60-0.5%335.20339.00330.80105,967
337.20+6.00+1.8%332.00340.80331.80135,597
331.20+8.60+2.7%322.80332.40322.60161,528
322.60-0.40-0.1%322.60328.60320.8050,578
323.00+3.40+1.1%320.80328.00320.8099,569
319.60-7.40-2.3%326.40327.20318.40111,199
327.00-1.00-0.3%327.40333.00326.0069,505
328.00+9.00+2.8%318.40329.40317.80117,317
319.00-1.20-0.4%320.20324.60316.6072,043
320.20+5.80+1.8%314.60322.20314.00119,807
314.40+3.40+1.1%314.00323.20314.00156,296
311.00+0.80+0.3%309.60316.00308.8058,907
310.20-5.00-1.6%316.20319.60309.20115,076
315.20+2.00+0.6%315.40320.00309.60117,498
313.20-11.80-3.6%324.60325.20308.00207,992
325.00+2.00+0.6%326.00335.80321.60218,297
323.00-1.40-0.4%324.00327.60319.8097,925
324.40+1.80+0.6%322.20331.40305.60261,810
322.60+6.80+2.2%315.80325.00311.80148,525
315.80+6.40+2.1%312.60320.20309.4088,600
309.40+2.60+0.8%306.80313.60306.6046,876
306.80-1.20-0.4%308.20309.20301.8057,779
308.00+1.00+0.3%304.00310.20302.0060,761
307.00+9.00+3.0%297.40307.60295.0072,079
298.00-2.20-0.7%299.80301.00295.0073,243
Ticker
Stockholm:BIOA_B
Asset type
Stock
Sector
Health care
Industry
Biotechnology
Exchange
Stockholm
Currency
SEK

What changed lately

Calls

Replays

  • Bioarctic (Stockholm:BIOA B) Q2 2026 Earnings Call

    Wed, Aug 26, 2026 · 3:30 AM ET

    Watch Transcript

  • Bioarctic (Stockholm:BIOA B) Q1 2026 Earnings Call

    Wed, May 20, 2026 · 1:00 AM ET

    Watch Transcript

  • Bioarctic (Stockholm:BIOA B) Q4 2025 Earnings Call

    Wed, Feb 18, 2026 · 3:30 AM ET

    Watch Transcript

Latest news

BioArctic publishes the Annual Report and Sustainability Report for 2025

Apr 21, 2026

The Nomination Committee's proposal for the election of Board members and Chairperson of the Board in BioArctic AB

Mar 27, 2026

Latest data on long-term, real-world treatment with lecanemab will be presented at the AD/PD™ 2026 congress

Mar 11, 2026

Number of shares and votes in BioArctic AB (publ) as of February 27, 2026

Feb 27, 2026

Invitation to presentation of BioArctic's fourth quarter report for October - December 2025 on February 18 at 9.30 a.m. CET

Feb 11, 2026

BLA for subcutaneous formulation of Leqembi® designated for Priority Review in China

Feb 9, 2026

Sales of Leqembi® totaled 20.7 billion yen in the fourth quarter 2025

Feb 6, 2026

Eisai submits Marketing Authorisation Variation to EMA for intravenous maintenance dosing every four weeks with Leqembi® (lecanemab)

Jan 26, 2026

Leqembi® Iqlik™ (lecanemab-irmb) supplemental Biologics License Application regarding subcutaneous starting dose granted Priority Review by the US FDA

Jan 25, 2026

BLA for subcutaneous formulation of Leqembi® accepted in China

Jan 6, 2026

All BioArctic AB news

Decks

BioArctic AB on 6ix

Sector
Health care
Industry
Biotechnology
News releases
15 in the last 12 months · 31 in all · newest Apr 21, 2026 · oldest 2025
Calls
14 calls with a replay · 14 with a transcript · latest Aug 26, 2026
Decks
10 decks · latest Aug 26, 2026

Where BioArctic AB is listed

ListingExchangeCountryCurrency
Stockholm:BIOAB · Home listing · This pageStockholmSwedenSEK
gettex:B9AgettexGermanyEUR
LSIN:0RV2LSINUnited KingdomSEK
Aquis:BIOABSAquisUnited KingdomSEK
OTC:BRCTFOTCUnited StatesUSD
LS Exchange:A2H5GSLS ExchangeGermanyEUR
Lang & Schwarz:A2H5GSLang & SchwarzGermanyEUR
Tradegate:B9ATradegateGermanyEUR
Frankfurt:B9AFrankfurtGermanyEUR
Hamburg:B9AHamburgGermanyEUR
Aquis:BIOABSAquisUnited KingdomSEK
Dusseldorf:B9ADusseldorfGermanyEUR
Munich:B9AMunichGermanyEUR
Stuttgart:B9AStuttgartGermanyEUR
Turquoise:BIOABSTurquoiseUnited KingdomSEK

Log in to ask 6ix AI your own questions about BioArctic AB.